STOCK TITAN

Can-Fite BioPharma Ltd. (CANF) Financials

CANF NYSE
FY2025 annual
Revenue $405K -39.9% YoY
Net Income -$9.8M n/m YoY
EPS (Diluted) -$5.97 YoY not available
Free Cash Flow -$9.0M n/m YoY
Market Cap $4.7M as of Nov 16, 2026
Price / Sales 11.7x on $405K revenue, FY2025
Price / Earnings n/m net loss, so no earnings multiple, FY2025
Price / Book 0.8x on $5.6M equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (20-F/6-K) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD FYE December

Newest figures come from the 20-F for FY2025, filed Mar 26, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CANF SEC filings page.

Can-Fite BioPharma Ltd. (CANF) reported $405K in revenue for fiscal year 2025, down 39.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).

Rhea AI CANF FY2025

The numbers depict a development-stage business where shrinking receipts coexist with rising research costs and recurring financing-funded cash needs.

FY2025 revenue fell 39.9% even as R&D rose 16.3%; the expense base remained committed while commercial inflow shrank. That combination points to a research program whose spending is not yet being funded by product revenue, rather than an operating model driven by customer volume.

FY2025 net loss of $9.83M was close to operating cash flow of -$8.95M, showing that the reported loss largely translated into cash consumption. Free cash flow was also -$8.95M while capital expenditures were only $2K, so reinvestment in physical assets was not the main cash drain.

Financing cash flow of $9.64M nearly offset operating cash flow of -$8.95M, meaning external financing funded the annual cash requirement rather than operations. Current liabilities rose 33.1% and the current ratio was 3.5x; alongside the reported 7.4-month liquidity comparison, that describes balance-sheet flexibility without operating self-funding.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Can-Fite BioPharma Ltd., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Altman Z-Score Distress
-27.77

Can-Fite BioPharma Ltd. scores -27.77, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $176.2M against total assets of $9.5M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
1/7

Can-Fite BioPharma Ltd. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality No Cash Backing
N/A

Can-Fite BioPharma Ltd. reported a net loss of $9.8M while operations used $8.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Can-Fite BioPharma Ltd. reported an operating loss of $9.9M against $284K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$405K
YoY-39.9%
5Y CAGR-11.9%

Can-Fite BioPharma Ltd. generated $405K in revenue in fiscal year 2025. This represents a decrease of 39.9% from the prior year.

EBITDA
-$9.9M
YoYn/m
5Y CAGRn/m

Can-Fite BioPharma Ltd.'s EBITDA was -$9.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.

Net Income
-$9.8M
YoYn/m
5Y CAGRn/m
10Y CAGRn/m

Can-Fite BioPharma Ltd. reported a net loss of $9.8M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.

EPS (Diluted)
-$5.97

Can-Fite BioPharma Ltd. earned -$5.97 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow
-$9.0M
YoYn/m
5Y CAGRn/m

Can-Fite BioPharma Ltd. recorded an outflow of $9.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.

Cash & Debt
$5.5M
YoY+14.6%
5Y CAGR-7.7%

Can-Fite BioPharma Ltd. held $5.5M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.

Shares Outstanding
3M

Can-Fite BioPharma Ltd. had 3M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity
-175.8%
YoY-30.8pp
5Y change+62.0pp

Can-Fite BioPharma Ltd.'s ROE was -175.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 30.8 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$6.7M
YoY+16.3%
5Y CAGR-10.9%
10Y CAGR+5.5%

Can-Fite BioPharma Ltd. invested $6.7M in research and development in fiscal year 2025. This represents an increase of 16.3% from the prior year.

Capital Expenditures
$2K
YoY-60.0%
5Y CAGR-40.1%

Can-Fite BioPharma Ltd. invested $2K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 60.0% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

CANF Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CANF annual income statement
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-FFY1620-FFY1520-F
Revenue$405K-39.9%$674K-9.3%$743K-8.3%$810K-5.0%$853K+11.8%$763K-62.5%$2.0M-46.8%$3.8M+384.2%$789KN/AN/A
R&D Expenses$6.7M+16.3%$5.8M-3.8%$6.0M-22.9%$7.8M-21.2%$9.8M-17.6%$12.0M+8.9%$11.0M+80.7%$6.1M+19.0%$5.1M-16.5%$6.1M+56.6%$3.9M
SG&A Expenses$3.7M+20.2%$3.0M+3.1%$3.0M+1023.6%$263K-43.6%$466K+47.0%$317K-89.7%$3.1M-3.0%$3.2M+10.1%$2.9M+4.9%$2.7M-0.1%$2.7M
Operating Income-$9.9Mn/m-$8.1Mn/m-$8.2Mn/m-$10.1Mn/m-$12.8Mn/m-$14.1Mn/m-$12.0Mn/m-$5.4Mn/m-$7.2MN/AN/A
EBITDA-$9.9Mn/m-$8.1Mn/m-$8.2Mn/m-$10.1Mn/m-$12.8Mn/m-$14.1Mn/m-$12.0Mn/m-$5.4Mn/m-$7.2MN/AN/A
Interest Expense$284K-2.4%$291K-42.5%$506Kn/m-$222KN/AN/AN/AN/AN/AN/AN/A
Income TaxN/AN/AN/AN/AN/AN/AN/A$4K-86.2%$29KN/AN/A
Net Income-$9.8Mn/m-$7.9Mn/m-$7.6Mn/m-$10.2Mn/m-$12.6Mn/m-$14.4Mn/m-$12.6Mn/m-$6.6Mn/m-$4.8Mn/m-$8.4Mn/m-$6.5M
EPS (Basic)-$5.97-$10.86-$17.92n/m-$30.00-$90.00n/m-$120.00-$420.00-$510.00n/m-$420.00N/AN/A
EPS (Diluted)-$5.97-$10.86-$17.92n/m-$30.00-$90.00n/m-$120.00-$420.00-$510.00n/m-$420.00N/AN/A
Diluted Shares (Avg)2M725,309426,111+56.7%271,915184,360+54.3%119,470N/AN/AN/AN/AN/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

CANF Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CANF annual balance sheet
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-FFY1620-FFY1520-F
Total Assets$9.5M+4.3%$9.1M-8.7%$10.0M+7.6%$9.3M-54.2%$20.3M+112.7%$9.5M+16.5%$8.2M+2.8%$8.0MN/AN/AN/A
Current Assets$9.4M+5.1%$9.0M-9.3%$9.9M+8.2%$9.2M-54.4%$20.1M+113.5%$9.4M+31.6%$7.1M-9.6%$7.9MN/AN/AN/A
Cash & Equivalents$5.5M+14.6%$4.8M+12.8%$4.3M+43.7%$3.0M-32.2%$4.4M-46.9%$8.3M+206.6%$2.7M-25.4%$3.6M+3.1%$3.5M-56.8%$8.1MN/A
Short-Term Investments$1K-80.0%$5K-73.7%$19K+137.5%$8K-96.6%$237K+216.0%$75K+17.2%$64Kn/m$0n/m$0n/m$0N/A
Accounts ReceivableN/A$0n/m$0N/AN/AN/AN/AN/AN/AN/AN/A
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0N/A
Total Liabilities$3.9M+6.5%$3.7M-1.7%$3.7M-22.1%$4.8M-18.1%$5.9M+70.2%$3.4M-39.8%$5.7M+16.1%$4.9MN/AN/AN/A
Current Liabilities$2.7M+33.1%$2.1M+1.6%$2.0M-19.3%$2.5M-8.4%$2.7M+115.1%$1.3M-61.2%$3.3M+4.9%$3.1MN/AN/AN/A
Non-Current Liabilities$1.2M-27.0%$1.6M-5.4%$1.7M-25.2%$2.3M-26.5%$3.1M+44.1%$2.2M-11.4%$2.5M+35.4%$1.8MN/AN/AN/A
Total Equity$5.6M+2.9%$5.4M-12.9%$6.2M+39.6%$4.5M-68.9%$14.4M+136.8%$6.1M+148.7%$2.4M-19.0%$3.0M+1.0%$3.0M-23.6%$3.9MN/A
Retained Earnings-$176.2Mn/m-$166.4Mn/m-$158.5Mn/m-$150.8Mn/m-$140.7Mn/m-$125.5Mn/m-$110.3Mn/m-$97.7MN/AN/AN/A

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

CANF Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CANF annual cash flow statement
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-FFY1620-FFY1520-F
Operating Cash Flow-$8.9Mn/m-$7.6Mn/m-$8.4Mn/m-$10.8Mn/m-$9.9Mn/m-$12.1Mn/m-$11.1Mn/m-$4.2Mn/m-$9.0MN/AN/A
Depreciation & Amortization$24K+242.9%$7K-53.3%$15K+7.1%$14K0.0%$14K+16.7%$12K-14.3%$14K0.0%$14K-26.3%$19KN/AN/A
Stock-Based Compensation$340K-6.1%$362K+38.7%$261K-0.8%$263K-43.6%$466K+31.3%$355K-7.8%$385K-28.0%$535K+178.6%$192KN/AN/A
Capital Expenditures$2K-60.0%$5K+150.0%$2K-77.8%$9K-18.2%$11K-57.7%$26K+766.7%$3K-90.9%$33K+371.4%$7KN/AN/A
Free Cash Flow-$9.0Mn/m-$7.6Mn/m-$8.4Mn/m-$10.8Mn/m-$9.9Mn/m-$12.1Mn/m-$11.1Mn/m-$4.2Mn/m-$9.0MN/AN/A
Investing Cash Flow-$2K-100.1%$1.5M+200.2%$498K-94.8%$9.5Mn/m-$14.5Mn/m-$26Kn/m-$3Kn/m-$33Kn/m-$29KN/AN/A
Financing Cash Flow$9.6M+43.7%$6.7M-26.6%$9.1MN/A$20.5M+15.7%$17.7M+73.9%$10.2M+131.8%$4.4M-1.9%$4.5MN/AN/A
Dividends PaidN/AN/AN/AN/A$2.6M+262.2%$715KN/AN/AN/AN/AN/A

Not reported in any period shown, so not listed: Share Buybacks.

CANF Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CANF annual financial ratios
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-FFY1620-FFY1520-F
Operating Margin-2456.8%-1206.2%-1103.0%-1246.4%-1505.5%-1853.1%-590.9%-141.7%-910.6%N/AN/A
Net Margin-2426.7%-1169.1%-1027.5%-1255.9%-1478.9%-1892.9%-621.3%-172.0%-613.7%N/AN/A
Return on Equity-175.8%-30.8pp-145.0%-22.7pp-122.3%+105.2pp-227.5%-139.8pp-87.7%+150.1pp-237.8%+279.2pp-517.0%-299.1pp-217.9%-55.7pp-162.3%+52.6pp-214.8%N/A
Return on Assets-103.3%-16.9pp-86.4%-10.0pp-76.4%+33.2pp-109.6%-47.3pp-62.3%+89.4pp-151.7%+2.8pp-154.4%-71.8pp-82.6%N/AN/AN/A
Current Ratio3.46-0.9x4.38-0.5x4.91+1.2x3.66-3.7x7.35-0.1x7.41+5.2x2.18-0.3x2.53N/AN/AN/A
Liabilities-to-Equity0.700.0x0.68+0.1x0.60-0.5x1.08+0.7x0.41-0.2x0.57-1.8x2.35+0.7x1.64N/AN/AN/A
Asset Turnover0.040.0x0.070.0x0.070.0x0.090.0x0.040.0x0.08-0.2x0.25-0.2x0.48N/AN/AN/A
FCF Margin-2210.1%-1133.8%-1136.2%-1334.6%-1157.0%-1584.4%-545.6%-109.6%-1138.0%N/AN/A

Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Can-Fite BioPharma Ltd. CANF FY2025 $405K -$9.8M N/A $4.7M —
NuCana plc NCNA FY2025 N/A -$39.5M N/A $3.6M —
Pulmatrix, Inc. PULM FY2025 N/A -$5.2M N/A $4.9M —
SeaStar Medical Holding Corporation ICU FY2025 $1.2M -$12.2M N/A $4.5M 53/100
CNS Pharmaceuticals, Inc. CNSP FY2025 N/A -$15.9M N/A $5.1M —
Xenetic Biosciences, Inc. XBIO FY2025 $3.0M -$2.7M -90.1% $3.5M 67/100

Frequently Asked Questions

Can-Fite BioPharma Ltd. (CANF) reported $405K in total revenue for fiscal year 2025. This represents a -39.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Can-Fite BioPharma Ltd. (CANF) revenue declined by 39.9% year-over-year, from $674K to $405K in fiscal year 2025.

No, Can-Fite BioPharma Ltd. (CANF) reported a net loss of $9.8M in fiscal year 2025.

Can-Fite BioPharma Ltd. (CANF) reported diluted earnings per share of -$5.97 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Can-Fite BioPharma Ltd. (CANF) had EBITDA of -$9.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Can-Fite BioPharma Ltd. (CANF) has a return on equity of -175.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Can-Fite BioPharma Ltd. (CANF) recorded an outflow of $9.0M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Can-Fite BioPharma Ltd. (CANF) recorded an outflow of $8.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Can-Fite BioPharma Ltd. (CANF) had $9.5M in total assets as of fiscal year 2025, including both current and long-term assets.

Can-Fite BioPharma Ltd. (CANF) invested $2K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Can-Fite BioPharma Ltd. (CANF) invested $6.7M in research and development during fiscal year 2025.

Can-Fite BioPharma Ltd. (CANF) had 3M shares outstanding as of fiscal year 2025.

Can-Fite BioPharma Ltd. (CANF) had a current ratio of 3.46 as of fiscal year 2025, which is generally considered healthy.

Can-Fite BioPharma Ltd. (CANF) had a liabilities-to-equity ratio of 0.70 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Can-Fite BioPharma Ltd. (CANF) had a return on assets of -103.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Can-Fite BioPharma Ltd. (CANF) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $4.7M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Can-Fite BioPharma Ltd. (CANF) trades at 11.7x sales, its market capitalization divided by $405K revenue, FY2025. The market capitalization is $4.7M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Can-Fite BioPharma Ltd. (CANF) held $5.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.9M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Can-Fite BioPharma Ltd. (CANF) has an Altman Z-Score of -27.77, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Can-Fite BioPharma Ltd. (CANF) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Can-Fite BioPharma Ltd. (CANF) reported a net loss of $9.8M while operations used $8.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can-Fite BioPharma Ltd. (CANF) reported an operating loss of $9.9M against $284K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top